ReviewNeuroRx : the journal of the American Society for Experimental NeuroTherapeutics2005
Neuroimaging and therapeutics in movement disorders.
Review in NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 72 citations in OpenAlex.
- Distinguishing patients with Parkinson's disease subtypes from normal controls based on functional network regional efficiencies.PloS one · 2014Article
- Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease.European journal of nuclear medicine and molecular imaging · 2011Article
- Article
- Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2009Review
- STN-stimulation in Parkinson's disease restores striatal inhibition of thalamocortical projection.Human brain mapping · 2009Article
- Neuroimaging and transcranial ultrasonography in Parkinson's disease.Current neurology and neuroscience reports · 2008Review
- Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2008Article
- Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Assessment of the progression of Parkinson's disease: a metabolic network approach.The Lancet. Neurology · 2007Review
- The assessment of neurological systems with functional imaging.Brain and language · 2007Review
- Changes in network activity with the progression of Parkinson's disease.Brain : a journal of neurology · 2007Article
- Quantification of Parkinson's disease-related network expression with ECD SPECT.European journal of nuclear medicine and molecular imaging · 2007Article
- Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2007Article
- Prodromal non-motor symptoms of Parkinson's disease.Neuropsychiatric disease and treatment · 2007Article
- Metabolic brain networks associated with cognitive function in Parkinson's disease.NeuroImage · 2007Article
- Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease.NeuroImage · 2006Article
- Imaging in cell-based therapy for neurodegenerative diseases.European journal of nuclear medicine and molecular imaging · 2005Review
- Single-photon emission computed tomography in neurotherapeutics.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2005Review
- Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease.Molecular imaging and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, we discuss the role of neuroimaging in assessing treatment options for movement disorders, particularly Parkinson's disease (PD). Imaging methods to assess dopaminergic function have recently been applied in trials of potential neuroprotective agents. Other imaging methods using regional metabolism and/or cerebral perfusion have been recently introduced to quantify the modulation of network activity as an objective marker of the treatment response. Both imaging strategies have provided novel insights into the mechanisms underlying a variety of pharmacological and stereotaxic surgical treatment strategies for PD and other movement disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.